Hepatitis B Treatment Recommendations

Search Knowledgebase

Topic Contents

Hepatitis B Treatment Recommendations

Topic Overview

The Canadian Association for the Study of the Liver has made recommendations for treating long-term (chronic) hepatitis B. These recommendations are based on the presence of hepatitis B antigens in your blood, the level of hepatitis B viral DNA (HBV DNA) in your blood, and the levels of your liver enzymes.

Chronic hepatitis B can be HBeAg-positive or -negative. This means a specific hepatitis B antigen (HBeAg) is present (positive) or is not present (negative) in your blood. High levels of HBV DNA and liver enzymes may be present in both of these types of chronic hepatitis. This points to an active viral infection and increased risk of liver damage.

Treatment with antiviral medicine is recommended if you are:1

  • HBeAg-positive and have high levels of HBV DNA, and your liver enzymes are above the normal level for 3 to 6 months.
  • HBeAg-negative and have lower levels of HBV DNA, and your liver enzymes are above the normal level.
  • Either HBeAg-positive or negative, have high levels of HBV DNA, and have significant scarring of the liver.

Treatment with antiviral medicine is not recommended if you are:1

  • HBeAg-positive and have high levels of HBV DNA, your liver enzyme levels are normal and you don't have cirrhosis.
  • HBeAg-positive or negative and have low levels of HBV DNA, and your liver enzyme levels are normal.

If you are either HBeAg-positive or -negative, have low levels of HBV DNA, and have cirrhosis, you may be monitored or may need a liver transplant.

The European Association for the Study of the Liver (EASL) also has guidelines for the treatment of chronic hepatitis B. According to the EASL, treatment should be considered for people with high levels of HBV DNA and/or higher-than-normal levels of the liver enzyme alanine aminotransferase (ALT), and moderate to severe liver inflammation. But the decision to treat should also consider a person's general health, age, and availability of antiviral medicines.2

References

Citations

  1. Sherman M, et al. (2007). Management of chronic hepatitis B: Consensus guidelines. Canadian Journal of Gastroenterology, 21(Suppl C): 5C–24C.
  2. European Association for the Study of the Liver (2009). EASL Clinical Practice Guidelines: Management of chronic hepatitis B. Journal of Hepatology, 50(2): 227–242.

Credits

By Healthwise Staff
Primary Medical Reviewer Anne C. Poinier, MD - Internal Medicine
Primary Medical Reviewer Kathleen Romito, MD - Family Medicine
Primary Medical Reviewer Donald Sproule, MD, CM, CCFP, FCFP - Family Medicine
Specialist Medical Reviewer E. Gregory Thompson, MD - Internal Medicine
Specialist Medical Reviewer Steven L. Flamm, MD, MD - Gastroenterology
Last Revised February 2, 2011

This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information.